C=x Bonded Directly Or Indirectly By An Acyclic Carbon Or Carbon Chain To Ring Carbon Of The Five-membered Hetero Ring (e.g., Tryptophan, Etc.) (x Is Chalcogen) Patents (Class 514/419)
Indomethacine per se or ester thereof (Class 514/420)
  • METHODS AND COMPOSITIONS FOR PROMOTING WOUND HEALING
    Publication number: 20120052110
    Abstract: Provided herein are compositions and methods that inhibit expression of Adam12 gene products, such as ADAM12 mRNA and/or ADAM12 polypeptides, as a therapeutic approach for the treatment of, or promotion of healing of, wounds.
    Type: Application
    Filed: August 4, 2011
    Publication date: March 1, 2012
    Applicant: Hospital for Special Surgery
    Inventors: Marjana TOMIC, Carl Peter Blobel, Asheesh Harsha
  • Apparatus and process for encapsulating capsules or other solid dosage forms within capsules
    Publication number: 20120052118
    Abstract: The present invention provides an apparatus and process for making softgel capsules having incorporated therein other solid dosage forms selected from the group consisting of pellets, smaller capsules, smaller tablets, sustained release solid dosage forms, immediate release solid dosage forms, extended release solid dosage forms and zero order release solid dosage forms, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies having means for suction; (d) a liquid fill system; (e) a wedge for heating gelatine ribbons and feeding said fill; and (f) two lateral dispensing devices said lateral dispensing devices including hoppers having said solid dosage forms, channelguides for transporting said solid dosage forms and a grasping claw for dispensing said solid dosage form into the softgel pocket formed in the rotary dies.
    Type: Application
    Filed: July 18, 2011
    Publication date: March 1, 2012
    Inventors: Carlos Salazar Altamar, Gustavo Anaya, Braulio Teran, Newman Aguas Navarro, Willmer Herrera
  • NANOTECHNOLOGY FORMULATION OF POORLY SOLUBLE COMPOUNDS
    Publication number: 20120052120
    Abstract: Embodiments of the present invention are directed to articles of manufacture, spheres having a diameter of 50 to 500 nanometers which contain poorly soluble drugs and methods of making such spheres. Embodiments of the present invention have particular application for the following drug candidates and closely related poorly soluble derivatives of such candidates: (i) indole hydrazinecarbothioamide [NSC 73306]; (ii) fenretinide (4HPR) [NSC 374551]; (iii) safingol [NSC 714503]; (iv) 17-allylamino demethoxygeldanamycin (17-AAG) [NSC 330507]; and (v) an aminoflavone drug [NSC 686288].
    Type: Application
    Filed: August 23, 2011
    Publication date: March 1, 2012
    Inventor: Trevor Percival CASTOR
  • Composition for relieving discomfort
    Patent number: 8124585
    Abstract: The invention relates to a method of controlling feelings of pain in infants or diseased or elderly persons using a complete nutrition or a nutritional supplement. The method comprises administering increased levels of folic acid, vitamin B6 and vitamin B12 or their functional equivalents.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: February 28, 2012
    Assignee: N.V. Nutricia
    Inventors: Robert Johan Joseph Hageman, Jacob Geert Bindels
  • ALLOSTERIC PROTEIN KINASE MODULATORS
    Publication number: 20120046307
    Abstract: The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.
    Type: Application
    Filed: October 16, 2009
    Publication date: February 23, 2012
    Applicant: UNIVERSITAET DES SAARLANDES
    Inventors: Matthias Engel, Wolfgang Fröhner, Adriane Stroba, Ricardo M. Biondi
  • Ethynylindole compounds
    Patent number: 8115014
    Abstract: As a compound having a potent oral activity and a long-lasting cysLT1/cysLT2 receptor antagonistic activity, the compound of the formula (I): which exhibits potent antagonistic activity against the cysLT1/cysLT2 receptor, and have long-lasting effects even in case of oral administration, and therefore is useful as an oral agent for preventing and/or treating a variety of diseases, for example, respiratory disease (for example, asthma (bronchial asthma, etc.), chronic obstructive pulmonary disease (COPD), pulmonary emphysema, chronic bronchitis, pneumonia (interstitial pneumonia, etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), apnea syndrome, allergic rhinitis, sinusitis (acute sinusitis, chronic sinusitis, etc.), pulmonary fibrosis, coughing (chronic coughing, etc.), and the like) was developed.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: February 14, 2012
    Assignee: ONO Pharmaceuticals, Co., Ltd.
    Inventors: Kazuyuki Ohmoto, Satoshi Itadani, Yoshisuke Nakayama, Jun Takeuchi, Manabu Fujita
  • Pharmaceutical compositions for the administration of aptamers
    Patent number: 8114440
    Abstract: Pharmaceutical compositions comprising an aptamer and an amino acid ester or amide or an aptamer; a divalent metal cation; and a carboxylic acid, a phospholipid, a phosphatidyl choline, or a sphingomyelin. Methods of treating or preventing a condition in an animal comprising administering to the animal the pharmaceutical compositions.
    Type: Grant
    Filed: April 10, 2006
    Date of Patent: February 14, 2012
    Assignee: Idexx Laboratories Inc.
    Inventor: Yerramilli V. S. N. Murthy
  • Novel Use of Fibrates
    Publication number: 20120035197
    Abstract: The present invention, which is applicable in the pharmaceutical industry, relates to the use of fibrates, in particular fenofibrate, especially in the form of a solid oral composition, for the manufacture of a drug for the treatment of sleep apnea, sleep apnea syndrome, in particular obstructive sleep apnea or obstructive sleep apnea syndrome.
    Type: Application
    Filed: December 31, 2009
    Publication date: February 9, 2012
    Applicant: Fournier Laboratories Ireland Limited
    Inventor: Eric Bruckert
  • S1P Receptors Modulators
    Publication number: 20120034270
    Abstract: The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with in-appropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.
    Type: Application
    Filed: October 16, 2009
    Publication date: February 9, 2012
    Applicant: Akaal Pharma Pty Ltd
    Inventors: Damian W. Grobelny, Gurmit S. Gill
  • COMPOSITION COMPRISING FREE AMINO ACIDS
    Publication number: 20120035234
    Abstract: A composition is described that can be used in prevention or treatment of patients having impaired gastro-intestinal tract function. The composition comprises free amino acids including about 9.0% to about 17.0% glutamic acid. Methods of treatment of impaired gastro-intestinal tract function are described.
    Type: Application
    Filed: October 18, 2011
    Publication date: February 9, 2012
    Applicant: Nestec S.A.
    Inventors: Constance Whippie, Olivier Ballevre, Julio Boza, Paul-André Finot
  • Indoles Useful in the Treatment of Inflammation
    Publication number: 20120029016
    Abstract: There is provided compounds of formula I, wherein ring R1a to R1c, R2a to R2e, and X have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of a respiratory disorder and/or inflammation.
    Type: Application
    Filed: December 30, 2009
    Publication date: February 2, 2012
    Applicant: BIOLIPOX AB
    Inventor: Peter Nilsson
  • METHOD OF TREATMENT OF NEPHROGENIC DIABETES INSIPIDUS
    Publication number: 20120029001
    Abstract: Nephrogenic diabetes insipidus is treated with statins.
    Type: Application
    Filed: July 30, 2010
    Publication date: February 2, 2012
    Applicant: UNIVERSITA' DEGLI STUDI DI BAR (Italian Nationality)
    Inventors: Giuseppe Procino, Maria Svelto, Giovanna Valenti, Monica Carmosino
  • NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS
    Publication number: 20120028995
    Abstract: The invention relates to compounds of general formula (I) as set forth in the claims as well as to the use of the compounds of the general formula (1) in the medical field, specifically for use in the suppression of DNA synthesis and inflammatory cytokine production as well as in the stimulation of anti-inflammatory cytokine production in vitro and in vivo. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.
    Type: Application
    Filed: July 19, 2011
    Publication date: February 2, 2012
    Applicant: IMTM GMBH
    Inventors: Siegfried ANSORGE, Ute BANK, Anke HEIMBURG, Heiko JULIUS, Karsten NORDHOFF, Michael TAEGER
  • HCV Inhibitor and Therapeutic Agent Combinations
    Publication number: 20120027721
    Abstract: The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and one or more different therapeutic agents administered in combination in an effective amount to the subject.
    Type: Application
    Filed: April 6, 2010
    Publication date: February 2, 2012
    Applicant: PTC THERAPEUTICS, INC.
    Inventor: Zhengxian Gu
  • INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR
    Publication number: 20120022121
    Abstract: Indole derivatives and analogous compounds and pharmaceutical compositions comprising the same are provided. Also provided are methods of using these compounds to inhibit tubulin polymerization in a cell associated with a proliferative disease or to treat cancer, metastatic cancer, resistant cancer or multidrug resistant cancer, including inter-alia: prostate cancer, breast cancer, melanoma, colon cancer and bladder cancer.
    Type: Application
    Filed: July 25, 2011
    Publication date: January 26, 2012
    Inventors: James T. DALTON, Duane D. MILLER, Sunjoo AHN, Charles DUKE, Dong Jin HWANG, Jun YANG
  • N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors
    Patent number: 8101649
    Abstract: This invention relates to N-acylhydrazone derivatives, which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: January 24, 2012
    Assignee: Neurosearch A/S
    Inventors: Antonio Nardi, Jeppe Kejser Christensen, Dan Peters, Tino Dyhring
  • Indole derivatives as S1P1 Receptor
    Patent number: 8101775
    Abstract: The invention relates to compounds of formula (I) wherein one of R5 and R6 is hydrogen or R2 and the other is (a) pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the S1P1 receptor.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: January 24, 2012
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, James Myatt, David Norton, Dean Andrew Rivers
  • PPAR ACTIVE COMPOUNDS
    Publication number: 20120015966
    Abstract: Compounds are described that are active on at least one of PPAR?, PPAR?, and PPAR?, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPAR?, PPAR?, and PPAR?.
    Type: Application
    Filed: September 23, 2011
    Publication date: January 19, 2012
    Inventors: Jack Lin, Byunghun Lee, Shenghua Shi, Chao Zhang, Dean R. Artis, Prabha N. Ibrahim, Weiru Wang, Rebecca Zuckerman
  • USE OF SUBSTITUTED CYANOPYRROLIDINES AND COMBINATION PREPARATIONS CONTAINING THEM FOR TREATING HYPERLIPIDEMIA AND ASSOCIATED DISEASES
    Publication number: 20120014907
    Abstract: Disclosed are methods and compositions for the treatment of hyperlipidemia and conditions associated therewith, such as CHD, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction (e.g. necrosis and apoptosis), dyslipidemia and post-prandial lipemia. The methods include administration of a therapeutically effective amount of a compound of formula (I), wherein R is substituted adamantly; and N is 0 to 3; in free form or in acid addition salt form, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: September 26, 2011
    Publication date: January 19, 2012
    Inventors: David Grenville Holmes, Thomas E. Hughes
  • Enhanced Natural Colors
    Publication number: 20120014934
    Abstract: A natural color is concentrated to intensify color range and to provide useful amounts of one or more of anti-oxidant, nutritional, and anti-inflammatory compounds derived from one or more pigment sources. In a preferred embodiment, the pigment source is a fruit, a vegetable, a legume, a spice, algae, or a combination thereof.
    Type: Application
    Filed: July 13, 2011
    Publication date: January 19, 2012
    Inventors: Paul Altaffer, Jeffrey M. Wuagneux, Pi-Yu Hsu
  • METHOD TO ASSAY PHOSPHOLIPID AND TRIGLYCERIDE TRANSFER ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN
    Publication number: 20120016000
    Abstract: The present invention is directed to a method for identifying an antagonist compound of microsomal triglyceride transfer protein (MTP), wherein the antagonist at least partially inhibits triglyceride transfer activity while not significantly inhibiting phospholipids transfer activity of MTP. In particular, the present invention is directed to assays for phospholipid (PL) and triglyceride (TG) transfer activity having considerably improved sensitivity. In addition, antagonist compounds that modulate the lipid transfer activity of MTP are provided. Kits for measuring the lipid transfer activity of MTP are also provided by the present invention.
    Type: Application
    Filed: July 15, 2011
    Publication date: January 19, 2012
    Inventors: M. Mahmmod Hussain, Jahangir Iqbal
  • Compounds for activating TGF-? signaling
    Patent number: 8097645
    Abstract: Compositions and methods for treatment and prevention of disorders and conditions characterized by reduced TGF-? signaling are described.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: January 17, 2012
    Assignees: The Board of Trustees of the Leland Stanford Junior University, SRI International
    Inventors: Anton Wyss-Coray, Mary J. Tanga
  • Unique Dual-Action Therapeutics
    Publication number: 20120010168
    Abstract: A new family of therapeutics which provides a controlled-release delivery platform for non-steroidal anti-inflammatory agents on an ester or an ester-carbonate backbone is disclosed herein. These agents are reversible inhibitors of acetylcholinesterase and are thus useful for clinical conditions benefiting from inflammation suppression and cholinergic intervention. These compounds are of the general formula wherein n=0, 1; X?C, Si, and N+ and NSAID=ibuprofen, naproxen, indomethacin and diclofenac. Other embodiments are also disclosed.
    Type: Application
    Filed: November 3, 2009
    Publication date: January 12, 2012
    Inventors: Jeffrey Laskin, Diane Heck, Mou-Tuan Huan, Karine Fabio, C. Jeffrey Lacey, Sherri Young, Pramod Mohanta, Christophe Guillon, Ned Heindel
  • METHODS FOR TREATING HEPATITIS C
    Publication number: 20120009142
    Abstract: In accordance with the present invention, compounds that inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of the invention, compounds useful in the treatment or prevention of HCV infection are provided.
    Type: Application
    Filed: June 13, 2011
    Publication date: January 12, 2012
    Applicant: PTC THERAPEUTICS, INC.
    Inventors: Gary Mitchell Karp, Peter Seongwoo Hwang, James Takasugi, Hongyu Ren, Richard Gerald Wilde, Anthony Turpoff, Alexander Arefolov, Guangming Chen, Jeffrey Allen Campbell, Christine Espiritu, Concetta Freund, Zhengxian Gu, Takashi Komatsu
  • ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY
    Publication number: 20120010263
    Abstract: The invention provides compounds of formula I wherein n, A, R, R?, R?, RO, X and Y are as defined in the description, and their preparation. The compounds of formula I are useful as pharmaceuticals.
    Type: Application
    Filed: September 22, 2011
    Publication date: January 12, 2012
    Inventors: Fabrizio Gasparini, Yves Auberson, Silvio Ofner, Terance William Hart, Kasper Zimmerman
  • Leukotriene Binhibitors
    Patent number: 8093253
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: January 10, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Romyr Dominique, Robert Alan Goodnow, Jr., Agnieszka Kowalczyk, Jianping Lou, Qi Qiao, Achyutharao Sidduri, Jefferson Wright Tilley
  • Dietary supplement and a method to enhance sleep and lucid dreaming
    Patent number: 8092840
    Abstract: A nutritional supplement for enhancing sleep and lucid dreaming in humans. It contains a combination of ingredients in proportions calculated to enhance lucid dreaming. The primary ingredients are Calea ternifolia, L-5-Hydroxytryptophan (L-5-HTP), and Vinpocetine. In addition, the nutritional supplement may include the secondary ingredient Melatonin and the tertiary ingredients Wild Lettuce Extract, Mugwort Extract, Dimethylaminoethanol Powder (DMAE), Passionflower Extract and Green Tea Extract. Further, various Vitamins may be added such as certain B vitamins, D and C, as well as Zinc, Magnesium and Calcium. The selection and amounts of the ingredients of the nutritional supplement promotes sleep and lucid dreaming in people who have taken the nutritional supplement prior to going to sleep.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: January 10, 2012
    Inventor: Jeff Luciano
  • Biomarkers for Inflammatory Bowel Disease and Methods Using the Same
    Publication number: 20120003158
    Abstract: The present invention provides various biomarkers of inflammatory bowel disease, including biomarkers for Crohn's disease and biomarkers for Ulcerative colitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of inflammatory bowel disease, methods for distinguishing between inflammatory bowel diseases, methods of determining predisposition to inflammatory bowel disease, methods of monitoring progression/regression of inflammatory bowel disease, methods of assessing efficacy of compositions for treating inflammatory bowel disease, methods of screening compositions for activity in modulating biomarkers of inflammatory bowel disease, methods of treating inflammatory bowel disease, as well as other methods based on biomarkers of inflammatory bowel disease.
    Type: Application
    Filed: April 8, 2011
    Publication date: January 5, 2012
    Inventors: Danny ALEXANDER, Jeffrey SHUSTER, Joshua KORZENIK, Garrett ZELLA
  • 4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
    Patent number: 8088800
    Abstract: The present invention relates to compounds of formulae (I) and (II) useful as opioid receptor antagonists for the treatment of obesity, wherein p is 0, 1, or 2; y is 0, 1, or 2; and z is 0, 1, or 2; X1 is CH2, CH, or N; to form a indolinyl, indolyl, or benzimidazole ring respectively and including applicable double bonds and/or hydrogen atoms; X2 is CH or N; R1 to R7, R3?, p, y, and z are as defined in the claims.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: January 3, 2012
    Assignee: Eli Lilly and Company
    Inventors: Dana Raε Benesh, Maria-Jesus Blanco-Pillado
  • PREVENTIVE OR THERAPEUTIC AGENTS FOR OPTIC NERVE DISORDERS COMPRISING 4,6-DICHLORO-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AS ACTIVE INGREDIENTS
    Publication number: 20110319463
    Abstract: A method for preventing or treating an optic nerve disorder, inhibiting retinal nerve cell death or recovering a neurofilament light chain expression level by administering to a patient a pharmacologically effective amount of at least one of the compound represented by the following formula (1): wherein R1 is a hydrogen atom or a lower alkyl group R2 is a hydrogen atom or a lower alkyl group; R1 and R2 may be joined to each other to form an aziridine ring, an azetidine ring, a pyrrolidine ring, a piperidine ring or an azepane ring; and R3 is a carboxyl group or an ester thereof or an amide thereof; or a salt thereof.
    Type: Application
    Filed: March 10, 2010
    Publication date: December 29, 2011
    Applicant: Saten Pharamaceuticals Co., Ltd.
    Inventors: Masaaki Sasaoka, Tomoko Umemoto, Hisayuki Seike, Masaaki Kageyama
  • INDOLE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20110319387
    Abstract: The invention relates to a compound of the following formula (I), or to a pharmaceutically acceptable salt thereof or to a stereoisomer or mixture of stereoisomers at any proportions, where: X1 is a CH2 or C?O group; X2 is a linear saturated or unsaturated carbohydrate chain with 8 to 24 carbon atoms; R1 is a hydrogen atom or an OH or (C1-C6)alkoxy group such as methoxy; and R2 is a CH3 or CH2OR3 group, with R3 being a hydrogen atom or a (C1-C6)alkyl, CO—(C1-C6)alkyl or NH—(C1-C6)alkyl group. The invention also relates to the use of said compound as a drug, in particular for treating neurodegenerative diseases, and to a method for preparing same.
    Type: Application
    Filed: March 2, 2010
    Publication date: December 29, 2011
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Fanny Schmidt, Bruno Figadere, Rita Raisman-Vozari, Pierre Champy
  • METHOD FOR REDUCING BLOOD PRESSURE USING INHIBITORS OF PLASMA KALLIKREIN
    Publication number: 20110318359
    Abstract: The present invention relates to methods of reducing blood pressure in a subject by administering a plasma kallikrein inhibitor.
    Type: Application
    Filed: December 2, 2009
    Publication date: December 29, 2011
    Inventors: Edward P. Feener, Allen Clermont
  • NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
    Publication number: 20110319386
    Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.
    Type: Application
    Filed: June 10, 2011
    Publication date: December 29, 2011
    Applicant: BrainCells Inc.
    Inventors: Carrolee Barlow, Todd A. Carter, Kai Treuner, Michael Lee
  • PRODUCTS COMPRISING N-PHENYLPROPENOYL AMINO ACID AMIDES AND USES THEREOF
    Publication number: 20110313014
    Abstract: The present invention relates to use of a composition comprising N-phenylpropenoyl amino acid amides for the preparation of a product to treat or prevent neurodegenerative disorders, cognitive decline, mild cognitive impairment, dementia, mood disorders, depression, sleep disorders, diseases involving protein aggregation in a human or animal, Alzheimer's disease, macular degeneration or diabetes. The invention further relates to products comprising N-phenylpropenoyl amino acid amides, including food and beverage products, food supplements, and pet food products, and methods for affecting cognitive performance of humans and animals.
    Type: Application
    Filed: February 3, 2010
    Publication date: December 22, 2011
    Applicant: NESTEC S.A.
    Inventors: Fabien Robert, Karin Kraehenbuehl, Denis Marcel Barron, Jane Durga
  • Novel Methods for the Treatment of Cancer
    Publication number: 20110311648
    Abstract: Compositions and methods for the treatment of malignancy and chronic viral infection are disclosed.
    Type: Application
    Filed: July 20, 2011
    Publication date: December 22, 2011
    Inventors: George C. Prendergast, Alexander J. Muller, James B. DuHadaway, William Malachowski
  • NARINGENIN COMPLEXES AND METHODS OF USE THEREOF
    Publication number: 20110312985
    Abstract: The invention relates to methods of treatment of hepatitis C, dyslipidemia, insulin resistance, and inflammation, with flavonoid-sugar complexes.
    Type: Application
    Filed: October 7, 2009
    Publication date: December 22, 2011
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Yaakov Nahmias, Martin L. Yarmush, Raymond T. Chung
  • MALIGNANT NEOPLASM TREATMENT PROTOCOL
    Publication number: 20110300227
    Abstract: Methods, compositions, and strategies for the treatment of malignant neoplasms are presented herein. The treatment modalities are directed towards exploiting characteristics of cancer cells as well as correcting defective biochemical pathways and systems in the body.
    Type: Application
    Filed: May 20, 2011
    Publication date: December 8, 2011
    Applicant: NORTH TEXAS MEDICAL ASSOCIATES
    Inventor: Ivan E. Danhof
  • USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASE
    Publication number: 20110301186
    Abstract: This invention is directed to methods and compositions for the treatment of cardiovascular disorders. Specifically, the invention is directed to compositions comprising vitamin E, statins and/or glutathione peroxidase mimetics; methods of treating diabetic patients expressing the Hp-2-2 haptoglobin genotype; a method of inhibiting or suppressing a cardiovascular disorder in a diabetic subject, treating cardiovascular disease in subjects exhibiting the Haptoglobin Hp-2-2 genotype; and methods of treating cardiovascular disease in subjects exhibiting the Haptoglobin Hp-2-2 genotype.
    Type: Application
    Filed: August 4, 2011
    Publication date: December 8, 2011
    Inventor: Andrew LEVY
  • NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT
    Publication number: 20110294841
    Abstract: The invention provides novel omega-3 oil formulations of one or more statins. These formulations are readily bioavailable. Notably, because the formulations of the invention contain an omega-3 oils as the major ingredient, they not only provide an antihypercholesterolemic effect due to the statin active ingredient, they also provide recommended daily dosages of omega-3 oils (i.e., approximately 1 gram of omega-3 oil per day), or a portion thereof. The invention also provides novel salts of one or more statins.
    Type: Application
    Filed: June 15, 2011
    Publication date: December 1, 2011
    Inventors: Hector GUZMAN, Örn ALMARSSON, Julius REMENAR
  • Compounds and compositions for treating infection
    Patent number: 8067401
    Abstract: Compounds from 14 Kenyan plants, including from the root of Dovyalis abyssinica and Clutia robusta have been characterized and isolated, and their uses are disclosed.
    Type: Grant
    Filed: September 6, 2007
    Date of Patent: November 29, 2011
    Assignee: International Patent Holdings LLC
    Inventors: Paul Kiprono Chepkwony, Maria Medina, Mitchell Medina
  • Methods and compositions for the treatment of metabolic disorders
    Patent number: 8067416
    Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: November 29, 2011
    Assignees: Merck Eprova AG, Biomarin Pharmaceutical Inc.
    Inventors: Daniel I. Oppenheimer, Emil D. Kakkis, Fredric D. Price, Alejandro Dorenbaum, Rudolf Moser, Viola Groehn, Thomas Egger, Fritz Blatter
  • Novel Formulation For L-Tryptophane Comprising Carbidopa/Benserazide
    Publication number: 20110288145
    Abstract: The present invention relates to the use of L-tryptophan and a peripheral degradation inhibitor of L-tryptophan for the manufacture of a medicament for prevention or therapy of pain, depressions, sleeping disorders and other serotonin dependent diseases of the CNS, wherein L-tryptophan is present in a retarded and the peripheral degradation inhibitor is present in a non-retarded formulation.
    Type: Application
    Filed: August 12, 2005
    Publication date: November 24, 2011
    Inventor: Joachim Kamprad
  • Anti-cytokine heterocyclic compounds
    Patent number: 8063094
    Abstract: Heterocyclic compounds which are inhibitors of Mitrogen-Activated Protein Kinase-Activated Protein Kinase-2 (MAPKAP-K2) as described, in addition to their use in the treatment of cytokine mediated diseases.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: November 22, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Asitha Abeywardane, Denise Andersen, Tina Marie Morwick, Roger John Snow, Yancey David Ward
  • SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
    Publication number: 20110281879
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Application
    Filed: January 12, 2011
    Publication date: November 17, 2011
    Applicant: ViroBay, Inc.
    Inventor: Craig Mossman
  • Combination therapy for the prevention of statin induced diabetes
    Publication number: 20110275649
    Abstract: Novel combinations comprising HMG CoA reductase inhibitors, or statins, with partial fatty acid oxidation inhibitors (pFOXi), and methods for their use, are disclosed. These combinations are useful in preventing or reducing the risk of developing diabetes which results from therapy with a statin.
    Type: Application
    Filed: May 3, 2011
    Publication date: November 10, 2011
    Applicant: Palmetto Pharmaceuticals LLC
    Inventor: Wayne H. Kaesemeyer
  • INDOLE COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR BIOLOGICAL ACTIVITY
    Publication number: 20110275677
    Abstract: The invention provides well-defined aryl and/or heteroaryl substituted indoles that are useful as sphingosine-1-phosphate agonists or antagonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: January 3, 2011
    Publication date: November 10, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Richard L. Beard, Haiqing Yuan, John E. Donello
  • COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE, AND INFLAMMATORY DISEASES
    Publication number: 20110269755
    Abstract: The disclosure provides compositions and methods for the treatment of vascular, autoimmune, and inflammatory diseases using a combination of an inosine monophosphate dehydrogenase (IMPDH) inhibitor and a HMG CoA reductase inhibitor.
    Type: Application
    Filed: December 9, 2010
    Publication date: November 3, 2011
    Applicant: Aspreva International Ltd.
    Inventors: Michael HAYDEN, Noel Hall
  • GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF
    Publication number: 20110269735
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.
    Type: Application
    Filed: April 13, 2011
    Publication date: November 3, 2011
    Applicant: CELERA CORPORATION
    Inventors: Dov SHIFFMAN, James J. DEVLIN, May LUKE, David A. ROSS
  • CHEWABLE GELLED EMULSIONS
    Publication number: 20110268770
    Abstract: An oral pharmaceutical composition in unit dose form, each unit dose comprising a statin within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion, one or both of the oil phase and the water phase whereof comprises a physiologically tolerable omega-3 acid ester.
    Type: Application
    Filed: October 8, 2009
    Publication date: November 3, 2011
    Applicant: PROBIO ASA
    Inventors: Tore Seternes, Kurt Ingar Draget, Ingvild Johanne Haug
  • Inhalable Formulations For Treating Pulmonary Hypertension And Methods Of Using Same
    Publication number: 20110265786
    Abstract: The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g., humans), wherein the formulation comprises at least one hypertension reducing agent, including but not limited to an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker or vasodilator, or any combination thereof. The formulations of the present invention may be a solution or suspension, and preferably are suitable for administration via nebulization. The present invention is also directed to a method and kit for treating a mammal suffering from pulmonary hypertension.
    Type: Application
    Filed: February 3, 2011
    Publication date: November 3, 2011
    Inventor: Imtiaz Chaudry